ArticleCancer management and research2026
Development and Validation of a Prognostic Nomogram for Endometrial Cancer Based on Systemic Immune-Inflammation Index and Key Clinicopathological Features.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop and validate a prognostic nomogram integrating systemic immune-inflammatory index (SII) and key clinicopathological features for predicting 2-, 3-, and 5-year overall survival (OS, primary surgery to all-cause death) in patients with Endometrial Cancer (EC), subgrouped into Survivors or Non-survivors, so as to address the unmet need for low-cost, dynamic risk stratification tools in EC precision medicine. Methods: A retrospective cohort of 341 patients with EC (per WHO 2020 criteria) from January 2015 to January 2023 was stratified randomly into training (60%, n=205) and validation (40%, n=136) sets (stratification factors: age). Independent prognostic factors were identified through LASSO and multivariate Cox regression analyses. A nomogram was constructed and evaluated using ROC curves, calibration plots, and decision curve analysis (DCA). Key indicators included pathological differentiation grade, lymphovascular space invasion (LVSI), and systemic immune-inflammatory index (SII). Results: Four independent predictors were identified: age (HR = 1.039, 95% CI: 0.994-1.086, Conclusion: This study successfully developed and validated a prognostic model for EC based on SII and pathological differentiation. The model significantly outperformed traditional clinical parameters and may serve as a valuable tool for early risk stratification and individualized management in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.